Medtronic PLC $MDT Shares Sold by HighTower Advisors LLC

Key Points

• HighTower Advisors cut its Medtronic stake by 70.3% in the second quarter, selling 929,333 shares and retaining 393,328 shares valued at approximately $30.8 million. Institutional investors and hedge funds collectively own 82.06% of MDT.
• Medtronic’s latest quarterly results exceeded expectations, with EPS of $1.55 and revenue of $9.81 billion, up 9.9% year over year. The company also raised its quarterly dividend to $0.72 per share, equal to a 3.1% yield.
• Analyst sentiment remains generally positive, with an average “Moderate Buy” rating and a consensus price target of $98.83, though recent targets have been mixed. Medtronic also faces potential legal uncertainty from an Applied Medical injunction case.

HighTower Advisors LLC cut its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 70.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 393,328 shares of the medical technology company's stock after selling 929,333 shares during the period. HighTower Advisors LLC's holdings in Medtronic were worth $30,770,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MDT. Anfield Capital Management LLC increased its stake in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 230 shares during the period. Monetary Solutions Ltd acquired a new stake in shares of Medtronic during the fourth quarter worth about $27,000. Acumen Wealth Advisors LLC purchased a new position in shares of Medtronic during the fourth quarter worth about $29,000. Imprint Wealth LLC purchased a new position in shares of Medtronic during the third quarter worth about $31,000. Finally, Basepoint Wealth LLC acquired a new position in Medtronic in the 4th quarter valued at about $32,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of MDT stock opened at $94.13 on Thursday. The stock has a fifty day moving average price of $83.88 and a 200 day moving average price of $86.08. The stock has a market cap of $120.49 billion, a PE ratio of 25.24, a P/E/G ratio of 2.47 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the firm earned $1.62 earnings per share. The company's revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. This is a positive change from Medtronic's previous quarterly dividend of $0.71. The ex-dividend date was Friday, June 26th. Medtronic's payout ratio is 77.21%.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm's stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wells Fargo & Company cut their price target on Medtronic from $114.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, June 4th. Truist Financial lowered their price objective on shares of Medtronic from $95.00 to $86.00 and set a "hold" rating on the stock in a research report on Thursday, June 4th. Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. BTIG Research restated a "buy" rating and set a $91.00 price objective on shares of Medtronic in a research report on Tuesday. Finally, The Goldman Sachs Group reduced their target price on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.83.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source